BofA Sees Sustained H2 Momentum for Straumann Post-Q2 Beat; Buy Rating Kept

06:55 AM EDT, 08/19/2026 (MT Newswires) -- BofA Global Research affirmed its investment opinion on Straumann Holding (STMN.SW), as the research firm expects "strong" underlying momentum to persist in the second half following better-than-expected second-quarter results. "Mgmt. confirmed the FY26 outlook ([high-single-digit] organic growth and [140-170-basis-point margin expansion at constant currency]). 2Q confirms continued share gains and healthy underlying demand, with 1H organic sales growth of 7.8%. We see continued support from premium implants and Digital Solutions. iEXCEL represented approximately 40% of Straumann's premium implant volumes in H1, while Digital Solutions delivered strong growth in [North America and Asia Pacific]. Mgmt remains on track to bring ClearCorrect to breakeven by the end of 2027. In China, the Shanghai campus should strengthen Straumann's local cost position ahead of [volume-based procurement] 2.0," the research firm said Wednesday, adding it sees potential for a guidance upgrade later in the year. The dental products company reported second-quarter revenue of 707 million francs, with an 8.5% organic growth, which analysts noted was 62 basis points ahead of consensus. In the first half, revenue was 1.38 billion francs, compared with 1.35 billion francs a year ago. Against this backdrop, BofA maintained its buy rating on the stock, with a price objective of 124 francs. The research firm noted the stock is part of its "25 for 2026" and "Europe 1 top ideas" lists.